Merrimack Pharmaceuticals Stock Today
| MACK Stock | USD 14.68 0.05 0.34% |
Performance11 of 100
| Odds Of DistressOver 69
|
Merrimack Pharmaceuticals is selling for 14.68 as of the 18th of April 2024. This is a -0.34 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 14.66. Merrimack Pharmaceuticals has more than 69 % chance of experiencing financial distress in the next few years of operation. However, it had a very good returns during the last 90 days. Equity ratings for Merrimack Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 24th of May 2023 and ending today, the 18th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 29th of March 2012 | Category Healthcare | Classification Health Care |
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts. Merrimack Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.. The company has 14.53 M outstanding shares of which 722.75 K shares are now shorted by private and institutional investors with about 6.23 trading days to cover. More on Merrimack Pharmaceuticals
Moving together with Merrimack Stock
| 0.61 | EOLS | Evolus Inc Financial Report 14th of May 2024 | PairCorr |
| 0.81 | JSPRW | Jasper Therapeutics | PairCorr |
Moving against Merrimack Stock
| 0.48 | LPTX | Leap Therapeutics Financial Report 20th of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Merrimack Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Merrimack Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Merrimack Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Richard Peters | |||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Machelen Kuur Cert | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Merrimack Pharmaceuticals report their recommendations after researching Merrimack Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Merrimack Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Merrimack Pharmaceuticals. The Merrimack consensus assessment is calculated by taking the average forecast from all of the analysts covering Merrimack Pharmaceuticals. | ||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Merrimack Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Merrimack Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Merrimack Pharmaceuticals is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||
Merrimack Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Merrimack Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Merrimack Pharmaceuticals' financial leverage. It provides some insight into what part of Merrimack Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Merrimack Pharmaceuticals (MACK) is traded on NASDAQ Exchange in USA. It is located in One Broadway, Cambridge, MA, United States, 02142 and employs 30 people. Merrimack Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 213.33 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Merrimack Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Merrimack Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Merrimack Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 14.53 M outstanding shares of which 722.75 K shares are now shorted by private and institutional investors with about 6.23 trading days to cover.
Merrimack Pharmaceuticals currently holds about 13.36 M in cash with (1.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.0.
Check Merrimack Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationMerrimack Pharmaceuticals holds a total of 14.53 Million outstanding shares. Over half of Merrimack Pharmaceuticals' outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Merrimack Pharmaceuticals. Please watch out for any change in the institutional holdings of Merrimack Pharmaceuticals as this could mean something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Merrimack Ownership Details
Merrimack Stock Price Odds Analysis
Proceeding from a normal probability distribution, the odds of Merrimack Pharmaceuticals jumping above the current price in 90 days from now is about 26.36%. The Merrimack Pharmaceuticals probability density function shows the probability of Merrimack Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Merrimack Pharmaceuticals has a beta of 0.1832. This indicates as returns on the market go up, Merrimack Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Merrimack Pharmaceuticals will be expected to be much smaller as well. Additionally, merrimack Pharmaceuticals has an alpha of 0.1542, implying that it can generate a 0.15 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Merrimack Pharmaceuticals to move above the current price in 90 days from now is about 26.36 (This Merrimack Pharmaceuticals probability density function shows the probability of Merrimack Stock to fall within a particular range of prices over 90 days) .
Merrimack Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Merrimack Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Merrimack Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Merrimack Pharmaceuticals' value.| Instituion | Recorded On | Shares | |
| Wittenberg Investment Management Inc | 2023-12-31 | 210.2 K | |
| State Street Corporation | 2023-12-31 | 196.7 K | |
| Northern Trust Corp | 2023-12-31 | 116.9 K | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 109.5 K | |
| Bank Of New York Mellon Corp | 2023-12-31 | 100.2 K | |
| Susquehanna International Group, Llp | 2023-12-31 | 80.6 K | |
| Goldman Sachs Group Inc | 2023-12-31 | 70.4 K | |
| Rosalind Advisors, Inc. | 2023-12-31 | 60 K | |
| Yakira Capital Management, Inc. | 2023-12-31 | 54.1 K | |
| Western Standard Llc | 2023-12-31 | 2.2 M | |
| Newtyn Management Llc | 2023-12-31 | 1.9 M |
Merrimack Pharmaceuticals Historical Income Statement
Merrimack Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Merrimack's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Merrimack Pharmaceuticals revenue and expense. Merrimack Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Merrimack Pharmaceuticals' Total Revenue is quite stable compared to the past year. Total Other Income Expense Net is expected to rise to about 1.1 M this year, although the value of Gross Profit is projected to rise to (486.2 K). View More FundamentalsMerrimack Stock Against Markets
Picking the right benchmark for Merrimack Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Merrimack Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Merrimack Pharmaceuticals is critical whether you are bullish or bearish towards Merrimack Pharmaceuticals at a given time. Please also check how Merrimack Pharmaceuticals' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Merrimack Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Price Ceiling Movement Now
Price Ceiling MovementCalculate and plot Price Ceiling Movement for different equity instruments |
| All Next | Launch Module |
Merrimack Pharmaceuticals Corporate Directors
Merrimack Pharmaceuticals corporate directors refer to members of a Merrimack Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Merrimack Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Merrimack Pharmaceuticals' board members must vote for the resolution. The Merrimack Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| George Demetri | Director | Profile | |
| John Mendelsohn | Director | Profile | |
| John Dineen | Director | Profile | |
| Vivian Lee | Director | Profile |
How to buy Merrimack Stock?
Before investing in Merrimack Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Merrimack Pharmaceuticals. To buy Merrimack Pharmaceuticals stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Merrimack Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Merrimack Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Merrimack Pharmaceuticals stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Merrimack Pharmaceuticals stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Merrimack Pharmaceuticals, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Merrimack Stock please use our How to Invest in Merrimack Pharmaceuticals guide.
Already Invested in Merrimack Pharmaceuticals?
The danger of trading Merrimack Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Merrimack Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Merrimack Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Merrimack Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Merrimack Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merrimack Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merrimack Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Merrimack Pharmaceuticals Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merrimack Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Merrimack Stock please use our How to buy in Merrimack Stock guide.Note that the Merrimack Pharmaceuticals information on this page should be used as a complementary analysis to other Merrimack Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Merrimack Stock analysis
When running Merrimack Pharmaceuticals' price analysis, check to measure Merrimack Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merrimack Pharmaceuticals is operating at the current time. Most of Merrimack Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Merrimack Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merrimack Pharmaceuticals' price. Additionally, you may evaluate how the addition of Merrimack Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |
Is Merrimack Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merrimack Pharmaceuticals. If investors know Merrimack will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merrimack Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.08) | Return On Assets (0.07) | Return On Equity (0.06) |
The market value of Merrimack Pharmaceuticals is measured differently than its book value, which is the value of Merrimack that is recorded on the company's balance sheet. Investors also form their own opinion of Merrimack Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Merrimack Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merrimack Pharmaceuticals' market value can be influenced by many factors that don't directly affect Merrimack Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merrimack Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Merrimack Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merrimack Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.